Library of 670 Novel Drug-Like Organic Compounds Available for Collaboration
A curated collection of approximately 670 novel small-molecule organic compounds synthesized for biomedical research projects. The library includes synthetic intermediates and fully elaborated molecules featuring diverse heterocyclic rings and amide bonds, all designed following Lipinski's Rule of Five for drug-likeness and amenable to analog preparation.
Overview
This offering provides access to a proprietary library of approximately 670 novel organic small molecules developed through medicinal chemistry research. The collection spans synthetic intermediates to fully elaborated drug-like compounds featuring diverse structural motifs, including heterocyclic rings and amide bonds. Each compound was designed following standard medicinal chemistry principles and adheres to Lipinski's Rule of Five, making them well-suited for pharmaceutical and biological applications. The library represents a valuable resource for drug discovery programs seeking novel chemical starting points or structure-activity relationship scaffolds.
Technical specifications
Compound characteristics:
- Approximately 670 novel organic compounds spanning multiple structural classes
- Includes both synthetic intermediates and fully elaborated small molecules
- Features diverse heterocyclic ring systems and amide bond linkages
- All compounds designed to comply with Lipinski's Rule of Five for drug-likeness
- Typical synthesis requires between 3 and 7 chemical steps
- Compounds are amenable to library synthesis and preparation of multiple analogs
- Originally designed to modulate biological targets with attention to in vivo pharmacokinetics
Synthesis approach:
- Guided by standard medicinal chemistry principles
- Designed to support structure-activity relationship development
- Optimized for biological activity and favorable pharmacokinetic profiles
Technology readiness level
The compounds are at varying stages of synthetic completion, with intermediates available for further derivatization and fully elaborated molecules ready for biological evaluation. Each compound has established synthetic routes, and the library is suitable for hit-to-lead optimization campaigns, target validation studies, or as a source of novel chemical matter for drug discovery partnerships.
About Saint Louis University
Saint Louis University is a private Jesuit research university with comprehensive academic programs and an expanding research portfolio across urban and health‑sciences campuses in Midtown St. Louis. Industry engages through co‑located hospital and clinical environments that enable observational studies, trials, and access to diverse patient populations, supported by centralized core facilities and research computing. The university’s location in a dense innovation economy—near major corporate R&D, a mature startup district, and the region’s emerging geospatial corridor—facilitates sponsored research, internships, and joint development. Research activity is supported by competitive federal funding from agencies such as NIH, NSF, and DoD. A dedicated technology transfer office provides IP management, licensing, and startup support with streamlined contracting for industry partners.
delivered to your inbox.